Teva (TEVA) Q1 FY26 earnings call: guidance and Q&A

Could you elaborate on the synergies between the Emalex acquisition and Teva's CNS franchise, particularly on the pediatric side? Also, what is the peak sales potential for Ecopipam, and what assumptions support that?

Richard Francis highlighted the significant unmet medical need in pediatric Tourette's, with low treatment rates and adherence, similar to previous successes with AUSTEDO and UZEDY. He noted synergies across patient services, managed markets, MSLs, and a small pediatric sales force. While not providing specific peak sales guidance, he emphasized the significant opportunity given the unmet need and Teva's expertise in movement disorders.

“We will have to put in place a small pediatric sales force to focus on nicotine. That said, it is worth noting just the deep expertise we have in movement disorders here at ever.”

asked by Louise Chen · answered by Richard Francis

Given the impressive growth in the innovative portfolio, including a 7% underlying growth this quarter, why is Teva maintaining a 'low single-digit growth' expectation for 2027, especially with new pipeline contributions like Ecopipam?

Richard Francis acknowledged the underlying strength but pointed to uncertainties around the IRA's impact on AUSTEDO in Q4 2026 and 2027, particularly regarding channel inventory and pricing. He reiterated confidence in AUSTEDO's long-term growth to over $3 billion peak sales, but noted that it's too early to update 2027 guidance after only one quarter, preferring to wait for more data on new launches like olanzapine LAI.

“Do we have any conservatism and concern and worry about the untreated patient population that still need to go on AUSTEDO. Do we have any worry about our ability to execute and get more patients on to AUSTEDO onto the right dose onto the right compliance inherence programs. No, absolutely not.”

asked by Glen Santangelo · answered by Richard Francis

With $2.5 billion to $3 billion in free cash flow expected, how will capital be allocated across additional BD, share repurchases, and debt paydown? Also, what is the latest on duvakitug's indication expansion strategy and competitive landscape?

Eli Kalif stated that Teva ended Q1 with $3.7 billion cash and expects to be north of $3.2 billion by year-end. He confirmed the potential for 1-2 more smaller BD deals, but nothing larger requiring additional financing in the short term, emphasizing the focus on maximizing shareholder value through a potential share buyback program. Eric Hughes explained that duvakitug's potential indications are categorized into T2, non-T2, and fibrotic, with specific choices to be announced by year-end based on market size, scientific justification, and regulatory success.

“What we actually announced this morning about the buyback, this is basically kind of a part of a natural evolution of our capital allocation, which really focuses us now on maximizing shareholder value.”

asked by Matthew Dellatorre · answered by Eliyahu Kalif

Given Ecopipam's history as an old Merck drug, is its patent protection primarily based on orphan exclusivity, potentially overlapping with AUSTEDO's IP? Also, has the FDA provided preliminary feedback on the sufficiency of trial durations for suicide ideation and neuro disorders?

Richard Francis clarified that Ecopipam is expected to be covered by orphan drug exclusivity for 7 years from FDA approval (into 2033/2034). Additionally, Emalex holds patents expiring in 2035 for methods of treating Tourette syndrome, with an additional application potentially extending to 2043. Eric Hughes noted the extensive data package, including two well-controlled studies, which is robust for an orphan disease. He stated that suicidality rates were extremely low and balanced with placebo, with no signal of motor events, suggesting the profile would be appreciated by regulators.

“We expect icupipam to be covered by orphan drug exclusivity. So that gives us 7 years from the date of FDA approval. So that sort of takes us into the 2033, 2034 time lines.”

asked by Umer Raffat · answered by Richard Francis

How should we think about Ecopipam's ramp-up post-approval, considering payer dynamics? Also, regarding AUSTEDO, what are the expectations for Q2 and Q3, given that expected destocking in Q1 didn't fully materialize?

Richard Francis expressed excitement for Ecopipam's potential due to unmet need but stated it's too early to provide specific ramp-up guidance, as Teva needs more time to assess patient access and therapy adoption. For AUSTEDO, he noted that the expected Q1 destocking didn't fully occur, suggesting it might play out in Q2 and Q3. However, leading indicators like TRx, milligrams, coverage, and new prescribers remain strong, supporting the long-term $3 billion+ peak sales target.

“What I always go back to, what I'm having these conversations internally is, okay, but what are we doing on the leading indicators, the TRx, the milligrams all the things we're doing around our coverage, new prescribers, the depth of prescribing. And all of those indicators are looking very much on track.”

asked by Chris Schott · answered by Richard Francis